What is GCAN's health score?

Greater Cannabis Company, Inc. (GCAN) has a TradeApes health score of 50 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is GCAN's estimated fair value?

Based on our 5-year discounted cash flow model, Greater Cannabis Company, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is GCAN undervalued or overvalued?

Our model currently rates GCAN as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for GCAN... Refresh in a moment for the full analysis.

Greater Cannabis Company, Inc. (GCAN)

Healthcare Inconclusive inconclusive mixed

$0.15

Updated: 2026-06-04

TradeApes Score

Financial Strength

20 Stressed

Operating Trend

70 Healthy

Relative Value

40 Weak

Capital Allocation

65 Healthy

Risk

80 Strong

Key Findings

+ Strong FCF growth — free cash flow up more than 20% year over year

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.